Data on Bristol-Myers Squibb Company’s Investigational Treatment for Alzheimer’s Disease Demonstrate Potential Therapeutic Window at Doses Below 100 mg in Phase II Safety and Tolerability Study

PARIS--(BUSINESS WIRE)--Bristol-Myers Squibb Company (NYSE: BMY) today announced the results of a Phase II study evaluating the safety and tolerability of the investigational gamma secretase inhibitor BMS-708163 in patients with mild-to-moderate Alzheimer’s disease. The randomized, double-blind, placebo-controlled study (CN156-013) demonstrated that BMS-708163 doses below 100 mg/day provide a potential therapeutic window for further evaluation in Phase III registrational studies. The study results were presented at the 2011 Alzheimer’s Association International Conference (AAIC).